Management and Outcomes of Pulmonary Embolism in the Oldest-Old
Eishan Beotra,Vincent Ngian,Fiona Tran,Kelvin Hsu,Fintan O'Rourke,Bin Ong
DOI: https://doi.org/10.2147/ijgm.s475403
IF: 2.145
2024-10-03
International Journal of General Medicine
Abstract:Eishan Beotra, 1 Vincent JJ Ngian, 1– 3 Fiona Tran, 1– 3 Kelvin Hsu, 1, 4 Fintan O'Rourke, 1, 3 Bin S Ong 1– 3 1 South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia; 2 Department of Ambulatory Medicine and Medical Assessment Unit, Bankstown-Lidcombe Hospital, South Western Sydney Local Health District, Sydney, NSW, Australia; 3 Department of Aged Care, Bankstown-Lidcombe Hospital, South Western Sydney Local Health District, Sydney, NSW, Australia; 4 Department of Respiratory Medicine, Bankstown-Lidcombe Hospital, South Western Sydney Local Health District, Sydney, NSW, Australia Correspondence: Bin S Ong, Department of Ambulatory Care, Eldridge Road, Bankstown, NSW, 2200, Australia, Email Background: Treatment for pulmonary embolism has expanded to include Direct Oral Anticoagulants (DOACs). The incidence of pulmonary-embolism (PE) in "oldest-old" age group (≥ 85 years) is rapidly increasing, but there is limited research on its management and clinical outcomes. Aim: To examine the differences in management and outcomes in those aged ≥ 85 years compared to other age groups. Methods: We performed a retrospective cohort-study of 373 consecutive patients with pulmonary embolism confirmed on imaging by Computed Tomography Pulmonary Angiogram (CTPA) or Ventilation Perfusion (VQ) Scan at a principal referral hospital in Sydney, Australia. Data collected include clinical and demographic data, Charlson comorbidity index, treatment type and outcomes including complications, recurrent venous thromboembolism, and mortality. Results: Across the age groups, DOACS were prescribed to 53.4% (n=199) of patients. In oldest-old patients with PE, LMWH bridging to warfarin was the most frequently prescribed treatment, used in 46.2% (n=18, 95% CI: 30.8%– 61.5%, p=0.003) of these patients. The mortality rate for patients on LMWH was 13.9% (n=5, 95% CI: 4.2%– 37.5%, p=0.553). Overall, major bleeding incidents were rare, occurring in just 1.7% (n=4, 95% CI: 0.4%– 3.3%) of patients, with no significant differences in outcomes across age groups. Conclusion: DOACs are increasingly used as the treatment modality of choice in atrial fibrillation but are less well studied in pulmonary embolism, particularly in oldest-old patients. We found that the safety and efficacy profile of DOACs in pulmonary embolism treatment is similar across the age groups. Our study does not support any change in treatment protocols of PE in the oldest old, but further studies are required to confirm our findings. Keywords: oldest-old, pulmonary embolism, anticoagulation, treatment, adverse outcomes The incidence of pulmonary embolism (PE) rises significantly with age. 1 The oldest-old (≥ 85 years) represent a disproportionately high proportion of patients admitted to hospital with PE. 2 The main treatment of PE for many years was Vitamin K Antagonists (VKA) bridged with Unfractionated Heparin (UFH) or Low Molecular Weight Heparin (LMWH). 3 Limitations of VKA such as wide inter dosing response, narrow therapeutic window and food/drug interactions apply to all age groups but are more pronounced in older age group, as is a higher incidence of major bleeding. 4 LMWH has largely replaced UFH in the treatment of PE, in the absence of severe kidney disease. 5 Direct Oral Anticoagulants (DOAC), introduced ten years ago, such as Rivaroxaban, Apixaban, Edoxaban and Dabigatran, have now been shown to be effective in the management of PE, with lower mortality and major bleeding rate. 6 However, the oldest-old constitute a small proportion of study subjects in these studies, warranting caution in extrapolating results. While DOACs have fewer drug interactions, limitations with concurrent liver, gastrointestinal and chronic kidney disease are more common barriers to use in older patients. 7 There is evidence of favorable risk profile in the use of DOACs for atrial fibrillation. 8 A meta-analysis found that the use of DOACs in atrial fibrillation was associated with a lower pooled risk of thromboembolic stroke with no significant difference in major bleeding. 9 However, studies on the use of DOACs in VTE for the oldest old are lacking. Current guidelines recommend a reduction in DOAC dose for atrial fibrillation with increasing age, but do not have the same recommendation for acute PE. 10 More data is required to confirm that this treatment regimen in PE is applicable to the oldest old population. There is growing evidence that outpatient treatment of PE is safe in selected patient groups. 11 Suitabilit -Abstract Truncated-
medicine, general & internal